Related Experiment Videos
[Observations and results of photodocumentation of retinal thromboses treated with Colfarit (author's transl)]
Insights
Acetosalicylic acid (Colfarit) effectively reopened retinal prethromboses and some central vein thromboses within 8 weeks. However, it showed no benefit for branch vein thromboses, with increased bleeding noted.
Area of Science:
- Ophthalmology
- Vascular Medicine
- Pharmacology
Context:
- Retinal vascular occlusive events pose significant visual threats.
- Acetosalicylic acid (Colfarit) is a commonly used antiplatelet agent.
- Evaluating drug efficacy in specific retinal vascular conditions is crucial.
Purpose:
- To assess the therapeutic effect of acetosalicylic acid (Colfarit) on different types of retinal vein thromboses.
- To document the temporal response to Colfarit treatment using photographic evidence.
Summary:
- Forty-one patients with retinal prethromboses, central vein thromboses, and branch vein thromboses were treated with acetosalicylic acid (Colfarit).
- Photographic documentation revealed that all 6 prethromboses and 7 of 14 central vein thromboses resolved within 8 weeks.
- No positive effect was observed in branch vein thromboses, with a notable increase in bleeding after prolonged treatment.
Impact:
- Acetosalicylic acid demonstrates potential efficacy in treating certain retinal vascular occlusions, particularly prethromboses and central vein thromboses.
- The findings suggest a specific therapeutic window and potential contraindications for Colfarit in branch vein thromboses.
- This study provides valuable data for clinical decision-making regarding antiplatelet therapy in retinal vascular diseases.
Abstract:
A report is given on 41 patients (6 prethromboses, 14 central veinthromboses and 21 branch vein thromboses), who were treated with acetosalicylic acid (Colfarit). The retinal charges were continuously documented by Polaroid photographs. Comparison of over one thousand pictures resulted in the following findings: All 6 prethromboses and 7 of the central vein thromboses were reopened within 8 weeks, even in the most advanced cases. The age of the patient was not a factor. The highpoint of the Colfarit effect was clearly identified in the photographs as occurring in the 5th week. No results with Colfarit were noted in the branch vein thromboses, in fact bleeding recurred in almost every case in the fifth week, when Colfarit was given for longer than 4 weeks in the dosage of 3 times 0.5 g daily.